RxDoctor Payments Data

Cristi Egenolf, MD

Family Medicine · Derry, NHNPI 1053391565

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 38.0% of the total.

$1,840in general payments, 2019–2025

Across 77 payments — averaging $23.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$700
  • Pfizer$257
  • Inspire Medical Systems, Inc.$226
  • AstraZeneca$107
  • Medtronic$102
  • Gilead$100
  • plus $349 from 13 others

What the payments were for

  • Food & beverage$1,82299%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,840 in reported general payments places this provider in the 85th percentile of 397 family medicine providers in New Hampshire.

See all family medicine providers in New Hampshire

Medicare billing

Part B allowed, 2024
$130,823
Medicare patients
344
Services billed
1,656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide14$14,515
XareltoRivaroxaban15$11,509
Atorvastatin Calcium178$1,752
Lisinopril173$1,545
Rosuvastatin Calcium157$1,393
Metoprolol Succinate79$1,249
Levothyroxine Sodium143$1,199
SynthroidLevothyroxine Sodium18$1,087
Pantoprazole Sodium64$1,035
Amlodipine Besylate113$767
Omeprazole44$767
Losartan Potassium88$711
Telmisartan23$661
Mirtazapine14$606
Propranolol Hcl ErPropranolol Hcl17$593

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$29$14,51514 claims
Mylan Inc.Atorvastatin Calcium$17$1,752178 claims
AbbVieSynthroid$700$1,08718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 397 family medicine providers in New Hampshire.

Other family medicine in Derry

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →